Literature DB >> 7947077

The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.

S Kehoe1, J Powell, S Wilson, C Woodman.   

Abstract

A retrospective analysis of ovarian cancer patients registered with the West Midlands Cancer Registry from 1 January 1985 to 31 December 1987 was undertaken to examine the variables associated with survival patterns, with particular reference to the specialty of the surgeon. A total of 1,654 patients were registered, of whom 1,184 had histologically confirmed ovarian cancer, with the operator identified. This consisted of 870 patients operated on by gynaecologists and 314 operated on by general surgeons. A significantly older population and a greater number of patients with stage III/IV disease were operated on by general surgeons. The median survival of patients under the general surgeons' care was 9.87 months, significantly lower (P < 0.0001) than the survival of the gynaecologists' patients (median survival = 29.1 months). Univariate and multivariate analysis correlated poor prognosis with advanced stage disease, older age, the presence of bulky residual tumour and a general surgeon as the operator. Stepwise Cox's proportional hazard analysis confirmed the general surgeon as an independent adverse prognostic factor with a relative hazard ratio of 1.34 (95% confidence interval = 1.05-1.71). Accepting the limitations of retrospective reviews, these findings suggest that every attempt be made to ensure that a gynaecologist is involved in the treatment of patients with ovarian pathology.

Entities:  

Mesh:

Year:  1994        PMID: 7947077      PMCID: PMC2033561          DOI: 10.1038/bjc.1994.440

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Ovarian cancer staging: does it require a gynecologic oncologist?

Authors:  A R Mayer; S K Chambers; E Graves; C Holm; P C Tseng; B E Nelson; P E Schwartz
Journal:  Gynecol Oncol       Date:  1992-11       Impact factor: 5.482

2.  Effect of surgical experience on the results of resection for oesophageal carcinoma.

Authors:  H R Matthews; D J Powell; C C McConkey
Journal:  Br J Surg       Date:  1986-08       Impact factor: 6.939

3.  Ovarian carcinoma--a 10-year series from a provincial hospital.

Authors:  J Timm
Journal:  Acta Obstet Gynecol Scand       Date:  1973       Impact factor: 3.636

4.  Treatment of advanced ovarian carcinoma in the elderly.

Authors:  D L Marchetti; S B Lele; R L Priore; M E McPhee; M M Hreshchyshyn
Journal:  Gynecol Oncol       Date:  1993-04       Impact factor: 5.482

5.  National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival.

Authors:  H N Nguyen; H E Averette; W Hoskins; M Penalver; B U Sevin; A Steren
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

6.  The impact of subspecialty training on the management of advanced ovarian cancer.

Authors:  S M Eisenkop; N M Spirtos; T W Montag; R H Nalick; H J Wang
Journal:  Gynecol Oncol       Date:  1992-11       Impact factor: 5.482

7.  Prognostic factors for overall survival in patients with advanced ovarian carcinoma.

Authors:  B Lund; P Williamson
Journal:  Ann Oncol       Date:  1991-04       Impact factor: 32.976

8.  Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment.

Authors:  M C Gulliford; A Petruckevitch; P G Burney
Journal:  BMJ       Date:  1991-08-24

9.  Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.

Authors:  D S Alberts; S Dahlberg; S J Green; D Garcia; E V Hannigan; R O'Toole; D Stock-Novack; E A Surwit; V K Malviya; C J Jolles
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860

  9 in total
  23 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

Review 2.  Recent advances: oncology.

Authors:  M H Tattersall; H Thomas
Journal:  BMJ       Date:  1999-02-13

3.  Centralisation of oesophagogastric cancer services: can specialist units deliver?

Authors:  M J Forshaw; J A Gossage; J Stephens; D Strauss; A J Botha; S Atkinson; R C Mason
Journal:  Ann R Coll Surg Engl       Date:  2006-10       Impact factor: 1.891

Review 4.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  Sarah E Cousins; Emma Tempest; David J Feuer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

5.  Racial differences in surgeons and hospitals for endometrial cancer treatment.

Authors:  Katrina Armstrong; Thomas C Randall; Daniel Polsky; Elizabeth Moye; Jeffrey H Silber
Journal:  Med Care       Date:  2011-02       Impact factor: 2.983

Review 6.  Centralisation of services for gynaecological cancer.

Authors:  Yin Ling Woo; Maria Kyrgiou; Andrew Bryant; Thomas Everett; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

7.  Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States.

Authors:  Shamly Austin; Michelle Y Martin; Yongin Kim; Ellen M Funkhouser; Edward E Partridge; Maria Pisu
Journal:  Health Serv Res       Date:  2012-12-03       Impact factor: 3.402

8.  Surgical outcomes in women with ovarian cancer.

Authors:  Laurie M Elit; Susan J Bondy; Lawrence P Paszat; Eric J Holowaty; Gillian M Thomas; Therese A Stukel; Mark N Levine
Journal:  Can J Surg       Date:  2008-10       Impact factor: 2.089

9.  Risk of malignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor.

Authors:  Onur Meray; Ilgın Türkçüoğlu; Mehmet Mutlu Meydanlı; Ayşe Kafkaslı
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

10.  When should surgical cytoreduction in advanced ovarian cancer take place?

Authors:  Igor E Martinek; Sean Kehoe
Journal:  J Oncol       Date:  2009-10-25       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.